

What is the role of risk benefit analyses? How does one best frame risk-benefit from the manufacturer, public and academic perspective?

John Ferguson, Novartis Vaccines and Diagnostics, USA

Industry representatives are collaborating with regulators and academics, to develop systematic approaches to balancing biopharmaceutical benefits and risks. This session describes the results of the collaboration, the impact of structured benefit-risk optimization on product development and the implications of these initiatives for authorization of vaccines.